PrognomiQ is a technology company.
PrognomiQ has raised $135.0M across 3 funding rounds.
PrognomiQ has raised $135.0M in total across 3 funding rounds.
PrognomiQ has raised $135.0M in total across 3 funding rounds.
PrognomiQ's investors include aMoon Fund, Balderton Capital.
PrognomiQ is a healthcare technology company specializing in developing transformative multi-omics test products aimed at enabling early detection and treatment of cancer and other complex diseases. By leveraging proprietary proteomic data at unprecedented volumes and depth, combined with genomic, metabolomic, and other health data, PrognomiQ creates powerful multi-omics platforms that provide deep biological insights. These insights facilitate the discovery of novel biomarkers and the development of early detection tests that could significantly impact patient outcomes and healthcare at large[1][2][3].
The company primarily serves patients and healthcare providers by addressing the critical problem of late-stage disease diagnosis, particularly in cancer. PrognomiQ’s multi-omics approach enhances early detection capabilities, which is essential for improving treatment success rates. The company has demonstrated promising results in early-stage cancer detection, such as non-small cell lung cancer, and is advancing clinical programs with substantial funding support, reflecting strong growth momentum and industry validation[1][3][4].
PrognomiQ was founded in September 2020 as a spinout from Seer, Inc., a company known for its Proteograph technology that enables comprehensive proteomic analysis. The founding team includes multidisciplinary experts in proteomics, multi-omics, data science, and clinical medicine. The idea emerged from the vision to harness Seer’s unique proteomic technology combined with other omics data to unlock early detection and treatment of complex diseases through high-quality molecular phenotyping[1][2].
Since its inception, PrognomiQ has evolved its focus toward developing multi-omics liquid biopsy platforms and has secured over $135 million in funding across multiple rounds, including a $34 million Series D in late 2024. This financial backing supports the company’s efforts to develop early detection tests for diseases like lung cancer, moving from lab-developed tests toward in vitro diagnostic products[1][4].
PrognomiQ rides the growing trend of precision medicine and multi-omics technologies that aim to revolutionize disease diagnosis and treatment by providing molecular-level insights. The timing is critical as advances in proteomics and other omics fields, combined with AI and big data analytics, are enabling unprecedented biological understanding. Market forces such as increasing demand for early cancer detection, rising healthcare costs, and the shift toward personalized medicine favor PrognomiQ’s approach. By pushing the boundaries of multi-omics integration and clinical application, PrognomiQ influences the broader ecosystem by setting new standards for biomarker discovery and diagnostic innovation[1][2][4].
Looking ahead, PrognomiQ is poised to expand its clinical programs and commercialize early detection tests, particularly for lung cancer, with plans to transition from lab-developed tests to in vitro diagnostics. Trends shaping its journey include continued advances in multi-omics technologies, regulatory acceptance of multi-omics diagnostics, and growing healthcare emphasis on early intervention. PrognomiQ’s influence is likely to grow as it validates and scales its platform, potentially transforming early disease detection paradigms and improving patient outcomes on a large scale[4].
In summary, PrognomiQ stands at the forefront of multi-omics healthcare innovation, leveraging cutting-edge proteomic and molecular data to unlock earlier and more precise disease detection, with a clear trajectory toward impactful clinical and commercial success.
PrognomiQ has raised $135.0M across 3 funding rounds. Most recently, it raised $34.0M Series D in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $34.0M Series D | aMoon Fund, Balderton Capital | |
| Mar 1, 2022 | $46.0M Venture Round | aMoon Fund, Balderton Capital | |
| Sep 1, 2020 | $55.0M Venture Round | aMoon Fund, Balderton Capital |